Prognostic models for patients with Hodgkin lymphoma are imperfect and do not allow a precise individualized therapy. A recent gene-expression profiling study, translated into a routine immunohistological test, identified genes of tumor-associated macrophages as being responsible for treatment outcome in patients with Hodgkin lymphoma. If this finding is confirmed by other investigators, it could be a major step towards personalized therapy for patients with Hodgkin lymphoma.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Prognostic value of lymphocyte-monocyte ratio at diagnosis in Hodgkin lymphoma: a meta-analysis
BMC Cancer Open Access 11 April 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Fuchs, M., Diehl, V. & Re, D. Current strategies and new approaches in the treatment of Hodgkin's lymphoma. Pathobiology 73, 126–140 (2006).
Küppers, R. The biology of Hodgkin's lymphoma. Nat. Rev. Cancer 9, 15–27 (2009).
Hasenclever, D. & Diehl, V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on advanced Hodgkin's disease. N. Engl. J. Med. 339, 1506–1514 (1998).
Hutchings, M. et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107, 52–59 (2006).
Steidl, C. et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N. Engl. J. Med. 362, 875–885 (2010).
Sánchez-Aguilera, A. et al. Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood 108, 662–668 (2006).
Devilard, E. et al. Gene expression profiling defines molecular subtypes of classical Hodgkin's disease. Oncogene 21, 3095–3102 (2002).
Dave, S. S. et al. Prediction of survival in folliculat lymphoma based on molecular features of tumor-infiltrating immune cells. N. Engl. J. Med. 351, 2159–2169 (2004).
Burger, J. A., Ghia, P., Rosenwald, A. & Caligaris-Cappio, F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 114, 3367–3375 (2009).
DeVita, V. T. Jr & Costa, J. Toward a personalized treatment of Hodgkin's disease. N. Engl. J. Med. 362, 942–943 (2010).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares he is a consultant for Seattle Genetics.
Rights and permissions
About this article
Cite this article
Diehl, V. Are macrophages the bad guys in Hodgkin lymphoma?. Nat Rev Clin Oncol 7, 301–302 (2010). https://doi.org/10.1038/nrclinonc.2010.71
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2010.71
This article is cited by
-
Prognostic value of lymphocyte-monocyte ratio at diagnosis in Hodgkin lymphoma: a meta-analysis
BMC Cancer (2019)
-
Tumorassoziierte Makrophagen
Der Pathologe (2015)
-
Correction: Hematology in 2010: New therapies and standard of care in oncology
Nature Reviews Clinical Oncology (2011)
-
Interim PET in lymphoma: a step towards standardization
European Journal of Nuclear Medicine and Molecular Imaging (2010)
